...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >COPD: NOVEL THERAPEUTICS AND MANAGEMENT STRATEGIES - SMI'S 7TH ANNUAL CONFERENCE (OCTOBER 19-20, 2015-LONDON, UK)
【24h】

COPD: NOVEL THERAPEUTICS AND MANAGEMENT STRATEGIES - SMI'S 7TH ANNUAL CONFERENCE (OCTOBER 19-20, 2015-LONDON, UK)

机译：COPD：新型疗法和管理策略-SMI第七届年度会议（2015年10月19日至20日，英国伦敦）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In 2004 the WHO estimated that 64 million people worldwide suffered from chronic obstructive pulmonary disease (COPD), with 3 million dying from related complications in 2005. Although many patients go undiagnosed, the number of people with the disease continues to increase, and by 2030 it is thought it will be the third most common cause of death in the world. With no cure for COPD, treatment of symptoms increased the European health bill by USD 10 million last year and the market is thought to increase to approximately USD 37.7 million by 2030. These staggering numbers were presented by Frank Thielman (Novartis Pharma) as he opened SMi's Seventh Annual COPD Conference in London, U.K. The meeting gathered experts and scientific pioneers in the respiratory area to discuss developments in known and new therapies, devices and diagnosis, including biomarker models to gain greater disease understanding. This report covers highlights from the 2-day meeting.
机译：据世界卫生组织（WHO）估计，2004年全球有6400万人患有慢性阻塞性肺疾病（COPD），其中300万人死于相关并发症。尽管许多患者得不到诊断，但该疾病的人数仍在增加，到2030年人们认为这将是世界上第三大最常见的死亡原因。由于无法治愈COPD，去年症状的治疗使欧洲的医疗费用增加了1000万美元，到2030年，市场被认为将增加到约3770万美元。这些惊人的数字是弗兰克·泰尔曼（Frank Thielman）（诺华制药）开业时提出的。 SMi在英国伦敦举行的第七届COPD年度会议此次会议聚集了呼吸领域的专家和科学先驱，讨论了已知疗法和新疗法，设备和诊断的发展，包括生物标记物模型，以加深对疾病的了解。该报告涵盖了为期2天的会议的要点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号